CSF1R and neoplasm: By analyzing the clinical outcome and tumor immune microenvironment from 109 stage III or high-risk stage II CRC patients, this study identified several important findings: (i) CRC patients with CSF1R c.1085 genotype A_A had a worse overall survival than patients with CSF1R genotype A_G.